Determination of the elimination half-life of fibroblast growth factor-23

Azarmindokht Khosravi, Carolee M. Cutler, Marilyn H. Kelly, Richard Chang, Richard E. Royal, Richard M. Sherry, Felasfa M. Wodajo, Neal S. Fedarko, Michael T. Collins

Research output: Contribution to journalArticlepeer-review


Context: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic disease caused by mesenchymal tumors that secrete fibroblast growth factor-23 (FGF-23), a newly-described vitamin D and phosphate-regulating hormone. Surgical removal of the tumor, the ectopic source of circulating FGF-23, offers the opportunity to determine the elimination half-life of FGF-23. Objective: The aim of the study was to determine the elimination half-life of FGF-23. Patients/Methods: The tumors were removed from three patients with TIO, and serum samples were taken every 30 min for up to 72 h after the operation. FGF-23 was measured by both a C-terminal/ intact assay and an intact assay, and the elimination half-life was determined by one phase exponential decay methodology. Setting: The Mark O. Hatfield Clinical Research Center of the National Institutes of Health, a tertiary referral clinical research center, was the setting for the study. Results: The elimination life of FGF-23 as determined by C-terminal/ intact and intact assays was 46 ± 12 and 58 ± 34 min, respectively. Conclusions: The plasma half-life of serum FGF-23 is in the range of 46-58 min.

Original languageEnglish (US)
Pages (from-to)2374-2377
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Issue number6
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Determination of the elimination half-life of fibroblast growth factor-23'. Together they form a unique fingerprint.

Cite this